AEZS vs. ADXN, ATHE, CMMB, GRTX, GHSI, MTEM, ERNA, GRAY, ABVC, and MIRA
Should you be buying Aeterna Zentaris stock or one of its competitors? The main competitors of Aeterna Zentaris include Addex Therapeutics (ADXN), Alterity Therapeutics (ATHE), Chemomab Therapeutics (CMMB), Galera Therapeutics (GRTX), Guardion Health Sciences (GHSI), Molecular Templates (MTEM), Eterna Therapeutics (ERNA), Graybug Vision (GRAY), ABVC BioPharma (ABVC), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical preparations" industry.
Aeterna Zentaris (NASDAQ:AEZS) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, community ranking, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.
Aeterna Zentaris received 407 more outperform votes than Addex Therapeutics when rated by MarketBeat users. Likewise, 62.26% of users gave Aeterna Zentaris an outperform vote while only 46.15% of users gave Addex Therapeutics an outperform vote.
Aeterna Zentaris has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500. Comparatively, Addex Therapeutics has a beta of 1.76, suggesting that its share price is 76% more volatile than the S&P 500.
Addex Therapeutics has a net margin of -644.66% compared to Aeterna Zentaris' net margin of -760.32%. Aeterna Zentaris' return on equity of -73.62% beat Addex Therapeutics' return on equity.
0.7% of Aeterna Zentaris shares are owned by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are owned by institutional investors. 0.1% of Aeterna Zentaris shares are owned by insiders. Comparatively, 15.0% of Addex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Aeterna Zentaris presently has a consensus target price of $60.00, suggesting a potential upside of 604.23%. Given Aeterna Zentaris' stronger consensus rating and higher probable upside, equities analysts plainly believe Aeterna Zentaris is more favorable than Addex Therapeutics.
In the previous week, Aeterna Zentaris had 6 more articles in the media than Addex Therapeutics. MarketBeat recorded 7 mentions for Aeterna Zentaris and 1 mentions for Addex Therapeutics. Addex Therapeutics' average media sentiment score of 0.75 beat Aeterna Zentaris' score of 0.45 indicating that Addex Therapeutics is being referred to more favorably in the news media.
Addex Therapeutics has lower revenue, but higher earnings than Aeterna Zentaris. Aeterna Zentaris is trading at a lower price-to-earnings ratio than Addex Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Aeterna Zentaris beats Addex Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Aeterna Zentaris News Delivered to You Automatically
Sign up to receive the latest news and ratings for AEZS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AEZS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aeterna Zentaris Competitors List
Related Companies and Tools
